Epigenetics in anesthesiology: an overview and clinical relevance Authors: Hyo-Jin Byon Published: 2026 ABSTRACT Epigenetics, the study of heritable changes in gene expression that occur without altering the underlying DNA sequence, has emerged as an important conceptual framework for anesthesiology. The epigenome is organized into three mechanistic tiers: cytosine methylation in DNA, chemical modification of histone proteins, and gene regulation by non-coding RNA molecules. Unlike a relatively stable genome, epigenetic patterns vary between cell types, change throughout the lifespan, and are modifiable by environmental exposures, including surgical stress and anesthetic drugs. These properties make epigenetic mechanisms particularly relevant to several problems encountered in anesthetic practice. For example, interindividual variability in responses to analgesics and anesthetics, pathophysiology of chronic pain and opioid tolerance, immune dysregulation in critical illness, and long-term cognitive consequences of perioperative exposure in vulnerable populations. This review aimed to explore the fundamental concepts of epigenetics for anesthesiologists; established roles in disease conditions relevant to anesthesiology, including pain, neurodegeneration, and inflammation; and the key considerations for designing and interpreting epigenetic research in the perioperative context. Understanding the epigenome offers both a new lens through which to view the clinical phenomena encountered daily in anesthetic practice, and a potential avenue toward more individualized, mechanism-informed patient care. INTRODUCTION Advances in genomic science over the past three decades have reshaped how clinicians think about disease mechanisms and treatment selection. However, a persistent puzzle remains: patients whose DNA sequences are indistinguishable at the relevant loci often differ substantially in terms of drug responses, disease trajectories, and surgical outcomes [1]. Sequence-level genetics leaves much of the variability unexplained. Epigenetics can help bridge this explanatory gap. The epigenome, a complementary regulatory layer, addresses this gap. Epigenetics studies the changes in gene activity that are heritable through cell division yet occur without any alteration of the DNA sequence [2]. If the genome is text, the epigenome is a system of punctuation, emphasis, and annotation that determines what the reader, the transcriptional machinery, actually processes at any given moment. Critically, epigenetic modifications are dynamic and potentially reversible, yet they can also be transmitted through cell division and across generations, properties that distinguish them from conventional genomic sequence variation. For anesthesiologists, epigenetics offers a conceptual bridge between acute pharmacological events in the operating room and their enduring biological consequences. The stress of surgery, hypoxia, inflammatory mediator release, and the anesthetic drugs themselves are all capable of modifying epigenetic marks [3]. These modifications can alter the expression of genes relevant to synaptic plasticity, nociceptive signaling, immune function, and neuronal maintenance, creating a molecular memory of the perioperative experience that may outlast the procedure by days, months, or years. Therefore, understanding the basic biology of these mechanisms is not merely an academic exercise. It is increasingly a prerequisite for interpreting the growing body of perioperative research and anticipating the next generation of diagnostic and therapeutic tools. This review aimed to provide anesthesiologists with a concise but rigorous introduction to epigenetic mechanisms, illustrate how these mechanisms operate in disease contexts directly relevant to our specialty, and offer practical guidance for those who wish to incorporate epigenetic measurements into clinical or translational research. GENETICS AND EPIGENETICS: KEY DISTINCTIONS To understand why epigenetics matters, we must recognize how it differs from classical genetics. The contrast between the two is of particular importance. First, cell identity across the body is epigenomic rather than genomic. Skeletal muscle cells and cortical neurons in the same patient carry the same DNA yet are functionally worlds apart, a divergence maintained by distinct configurations of epigenetic marks on an otherwise shared genetic scaffold [2,3]. The same logic applies at the interindividual level; two patients with identical sequences at an opioid receptor gene may still differ considerably in receptor density if their epigenetic configurations at that locus diverge. Second, epigenomic landscapes are not fixed at birth, but continue to evolve. Unlike mutations that, once established, are permanent, epigenetic marks are continuously remodelled as organisms develop and age [2]. For example, a drug, surgical stress, or metabolic shift encountered during early brain development leaves a different epigenomic imprint than that encountered decades later, a distinction with direct implications for perioperative risk across the age spectrum. Third, the modifiability of epigenetic marks cuts in both directions; environmental exposure can perturb them, but pharmacological interventions can also correct them. Drugs that inhibit DNA methyltransferases (DNMTs) or histone deacetylases (HDACs) have already been licensed for oncological indications, and the same classes of compounds are now being explored as tools to reverse adverse perioperative epigenomic changes. Fourth, once established, epigenetic marks are not erased during cell division, but are propagated to daughter cells, ensuring that a regulatory decision made by the progenitor is inherited by its progeny [2,4]. Under certain circumstances, this inheritance extends across generations through the germline, raising the possibility that anesthetic exposure experienced by parents can leave a biological legacy in children who were never exposed themselves. These four properties have substantial clinical significance. Divergent disease courses in genetically identical twins, which is a puzzle in classical genetics, become interpretable when epigenomic divergence is considered. More directly, they imply that pharmacological and physiological events in the perioperative period are not simply transient; they may write durable instructions to the regulatory apparatus of neurons, immune cells, and even germ cells. TYPES OF EPIGENETIC MODIFICATION DNA methylation Among the known epigenetic marks, cytosine methylation at CpG dinucleotides is the most extensively mapped. The responsible enzymatic machinery is divided functionally: DNMT1 operates during replication, copying the methylation signature from the parental strand onto the daughter strand to maintain existing patterns, whereas DNMT3a and DNMT3b establish de novo methylation at previously unmodified sites (Table 1, Fig. 1). Dense CpG clusters at promoters and CpG islands silence their downstream genes when methylated through a two-pronged mechanism. Methyl substituents directly impede activator binding to their recognition sequences, and proteins that recognize methylated cytosines (such as MeCP2) act as bridging adapters that draw in chromatin-compacting repressor complexes [3,5]. Conversely, the active removal of methyl groups is mediated by the ten-eleven translocation (TET) family of dioxygenases, which oxidize 5-methylcytosine through a series of intermediates (5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine) before base-excision repair restores the unmodified cytosine [6]. Beyond individual gene regulation, DNA methylation coordinates genome-scale programs including X-chromosome inactivation and parent-of-origin-dependent genomic imprinting. These mechanisms are of significant theoretical interest. In the context of pain and anesthesia, TET1-mediated demethylation of the promoters of genes encoding mu-opioid receptors (MORs) and voltage-gated potassium channels (Kv1.2) in dorsal root ganglion neurons has been demonstrated to alleviate neuropathic pain by restoring the expression of these key modulators of nociceptive transmission [7]. Local anesthetics, whose classical mechanism of action is sodium channel blockade, have also been shown to exert DNA demethylating effects in certain cancer cell lines, indicating that epigenetic actions may complement or modify their primary pharmacological activities [8]. Histone modification The meters of DNA housed within each nucleus must be radically compacted to fit, and this is achieved by spooling it around protein cylinders (octamers built from pairs of histones H2A, H2B, H3, and H4) to form the nucleosome, the repeating structural and regulatory unit of chromatin. The flexible N-terminal tails of each histone project outward from the nucleosome surface and serve as docking platforms for an extensive array of post-translational modifications, including acetylation, methylation, phosphorylation, ubiquitination, sumoylation, and the more recently characterized metabolically linked acyl groups, such as succinyl, butyryl, and lactyl moieties [9,10]. The acetylation of lysine residues on histone tails, catalyzed by histone acetyltransferases (HATs), neutralizes the positive charge of lysine, loosens the electrostatic interaction between histones and DNA, and tilts the local chromatin toward an open, transcription-permissive state. The reverse reaction, which is catalyzed by HDACs, restores compaction and gene silencing. Histone methylation, which is deposited by histone methyltransferases (HMTs) and removed by lysine demethylases (KDMs), carries a more nuanced message: H3 lysine 4 trimethylation (H3K4me3) marks transcriptionally active promoters, whereas H3K9 and H3K27 trimethylation recruit the silencing machinery (Table 1) [3,9]. An additional layer of complexity—the ‘histone code’—arises from the combinatorial logic whereby co-occurring marks on the same nucleosome generate outputs not predictable from any single modification alone. The two modification systems were not independent. Genome surveys have consistently found that silenced promoters carry both repressive histone marks and high methylation, and biochemical studies have shown that the enzyme complexes responsible for depositing or interpreting these marks are interlocked, a molecular architecture that ensures that chromatin compaction and DNA methylation reinforce rather than counteract each other [3,5]. Non-coding RNA regulation The third regulatory dimension is provided by RNA molecules, which are transcribed from the genome, but are never translated into proteins. Among them, microRNAs (miRNAs)—typically around 22 nucleotides long—operate through a surveillance mechanism: after being loaded into the RNA-induced silencing complex (RISC) effector complex, they patrol the 3’-untranslated regions of protein-coding transcripts, and when a sufficiently complementary target is found, the bound message is either cleaved or its translation is stalled (Table 1) [11]. Long non-coding RNAs (lncRNAs, > 200 nucleotides) act through various mechanisms; some tether chromatin-remodeling complexes to specific genomic addresses, others modulate methylation patterning, and others function as molecular sponges that sequester miRNAs or regulatory proteins [11]. Notably, ncRNAs do not operate in isolation from other epigenetic layers. They feed back into the DNA methylation and histone modification machinery, modulating the activity of the enzymes that write or erase these marks; reciprocally, the same enzymes regulate the accessibility of the ncRNA genes themselves. The result is a tightly coupled network in which a perturbation at any node, whether by an anesthetic drug, an inflammatory signal, or metabolic stress, can propagate effects across all three regulatory tiers (Fig. 1). EPIGENETIC MECHANISMS AND PERIOPERATIVE OUTCOMES Epigenetic dysregulation has been identified across a wide range of diseases, many of which directly intersect with anesthesiology (Table 1). A selective overview of the most relevant contexts is as follows. Chronic pain and opioid pharmacology Epigenetic mechanisms are centrally involved in the transition from acute to chronic pain and the development of opioid tolerance. In a rodent model of peripheral neuropathy, partial sciatic nerve ligation was shown to selectively induce histone hypoacetylation within C-fibers, suppressing transcription at the MOR and Nav1.8 sodium channel loci, thereby altering the sensitivity of primary afferents to both noxious stimuli and opioid analgesia [12]. In animal models of inflammatory pain, pharmacological inhibition of class II HDACs in the spinal cord attenuates thermal hyperalgesia [13]. Silencing of GAD65, a key enzyme in GABAergic neurotransmission, through epigenetic mechanisms, has been directly linked to the maintenance of persistent pain states, an effect reversed by HDAC inhibitor treatment [14]. In the context of opioid tolerance, preclinical (animal) data from models of sustained morphine exposure and cocaine dependence revealed system-wide histone acetylation remodeling, lending support to the view that epigenomic reprogramming is a common mechanism through which drugs of dependence reshape neural circuitry [15]. In an animal study, pharmacological HDAC blockade was shown to attenuate the locomotor sensitization that develops following a single morphine challenge in rodents [16]. The stress response associated with chronic pain, encompassing the hypothalamic-pituitary-adrenal axis activation and sustained glucocorticoid signaling, can drive histone deacetylation at pain-regulatory loci, further amplifying nociceptive sensitivity [3]. These findings suggest that targeting the epigenetic machinery could offer a novel therapeutic approach for patients with refractory chronic pain, an area of unmet need that is directly relevant to pain medicine practitioners. In an animal model, the blockade of macrophage inflammatory protein 2 and C-X-C chemokine receptor type 2 (CXCR2) signaling, which is upregulated via histone H3 acetylation at their promoters after peripheral nerve injury, has been shown to attenuate neuropathic pain [17]. Postoperative cognitive dysfunction and neurodegeneration Evidence that anesthetic exposure can alter the expression of enzymes responsible for modifying DNA and histones raises the question of whether perioperative epigenomic changes accelerate or unmask the underlying neurodegenerative processes, particularly in older surgical patients whose epigenomic buffering capacity is already diminished by age-related drift [18,19]. Postoperative cognitive dysfunction and delirium are among the most clinically consequential complications in this population, and epigenetic mechanisms are increasingly implicated in their pathophysiology. Pediatric concerns differ according to the mechanism. During the critical windows of neurodevelopment, the brain is engaged in high-rate synaptogenesis, axonal pruning, and circuit refinement processes that depend on precisely timed epigenomic transitions. Animal studies have shown that when anesthetic exposure falls within these windows, the methylation and histone modification patterns at cognition-related loci, notably brain-derived neurotrophic factor (BDNF) and c-Fos, are disrupted in ways that alter the synaptic architecture and impair learning [20,21]. Large human clinical studies, such as the General Anesthesia compared to Spinal anesthesia and the Pediatric Anesthesia and Neurodevelopment Assessment (GAS and PANDA) trials, have provided reassurance that brief, single general anesthetic exposures before the age of 3 years have minimal detectable neurodevelopmental impact. However, multiple or prolonged exposures continue to be associated with subtle learning and behavioral differences in these human cohorts [22], and the epigenomic mechanisms that may mediate a dose-response relationship remain an active area of investigation. Immune function and sepsis Immune cells provide a clear demonstration of how reversible epigenomic reprogramming produces lasting functional changes. In in vitro human monocyte models, after the first encounter with a bacterial endotoxin, surviving monocytes become tolerant, and a second challenge with the same stimulus elicits a blunted cytokine output. This tolerance is maintained by the selective removal of activating histone marks, specifically H4 acetylation and H3K4me3, from inflammatory gene promoters [23]. Crucially, this reprogramming is gene-specific rather than global and silences effector cytokines while leaving homeostatic gene expression intact, a distinction with obvious relevance to the immunoparalysis characteristics of late-stage sepsis [24]. The immunosuppressive state observed in patients with sepsis at the cellular level mirrors the findings from these in vitro endotoxin tolerance models, supporting their translational validity [23]. The opposite process, trained immunity, indicates that the same epigenomic plasticity can be effectively deployed. In human monocyte and macrophage models, a prior encounter with beta-glucan, a fungal cell wall component, activates histone marks on metabolic and immune gene promoters in macrophages. These newly marked cells switch toward aerobic glycolysis under HIF1α regulation and respond to subsequent challenges with greater speed and force than naïve macrophages [23,25]. Both tolerance and training are mediated in part by the non-coding RNA regulatory layer: miR-146a attenuates lipopolysaccharide-driven inflammation by depleting the signaling adapter TRAF6, contributing to the blunted cytokine responses of tolerant cells. In contrast, elevated miR-155 in an animal model of experimental sepsis has been associated with amplified autophagy, reduced cytokine release, and preserved pulmonary architecture [26]. EPIGENETIC EFFECTS OF ANESTHETIC AGENTS Propofol Propofol, the most widely used intravenous anesthetic, has been shown to modulate multiple epigenetic layers, notably histone modifications and non-coding RNA regulation, although with effects that are context-dependent and sometimes opposing (Table 2). In an animal study, propofol administered during early gestation inhibited histone acetylation in offspring brain tissue, producing learning and memory deficits that persisted into adulthood [27]. In contrast, an animal study found that propofol increased H3 acetylation in the astroglial cells of adult animals, a finding that may reflect a neuroprotective glial adaptation distinct from its actions in neurons [28]. At the non-coding RNA level, an animal study found that propofol and sevoflurane drive distinct and non-overlapping hippocampal miRNA profiles in rodents, and each agent selectively reprogrammed a different subset of miRNAs involved in neuronal differentiation and apoptotic signaling [29]. In another animal study, propofol sedation broadly reshaped the hippocampal lncRNA transcriptome, affecting messenger RNA (mRNA) stability and translation across a wide gene network [30]. In humans, a prospective matched-case study comparing propofol-based total intravenous anesthesia (TIVA) with sevoflurane-based volatile anesthesia in colorectal cancer surgery found that each technique stamped distinct lncRNA signatures on circulating blood: the TIVA signature clustered around immune activation and antitumor pathways, while the volatile signature indicated suppression of natural killer cell and cytotoxic T-lymphocyte function [31]. Isoflurane Neonatal isoflurane exposure has been consistently linked to epigenetic perturbations in the developing brain (Table 2). In rodent models, isoflurane increases the expression and activity of DNMT1, predisposing a wide array of neuronal genes to inappropriate silencing via hypermethylation [20]. This and the following isoflurane findings were derived from animal studies unless otherwise specified. Intergenerational animal studies have further demonstrated that paternal isoflurane exposure can transmit neurobehavioral abnormalities to the offspring through epigenetic mechanisms, although the specific germline modifications involved remain less well-characterized than those for sevoflurane [4]. Sevoflurane Sevoflurane is one of the most extensively studied anesthetics in epigenetic research (Table 2). In an animal study, neonatal exposure in rodents reduced the abundance of acetylated H3 and H4 in the hippocampal tissues, compacting chromatin in ways that translated into fewer dendritic spines, lower synaptic protein abundance, and impaired plasticity [32]. In another animal study, sevoflurane suppressed the circadian clock gene Period2 (Per2) through the loss of H4 acetylation at its promoter, potentially disrupting the molecular timekeeper that coordinates homeostatic gene regulation [33]. A mechanistically important observation from a neonatal mouse study was that sevoflurane reduces SET domain-containing 1B (SETD1B)-mediated H3K4me3 at the CXCR4 promoter in the hippocampus, leading to reduced CXCR4 expression, NLRP1/Caspase1-driven neuronal pyroptosis, and cognitive impairment. Restoration of SETD1B expression rescues both gene expression and cognitive performance in this animal model [34]. At the DNA methylation level, an animal study found that neonatal sevoflurane exposure causes hypermethylation of synaptic, memory-associated, and stress-responsive genes in the hippocampus, providing a molecular basis for the learning and memory deficits observed in this animal model [35]. In the non-coding RNA domain, animal studies have shown that sevoflurane and propofol drive non-overlapping miRNA changes in rodent hippocampal tissue [29], and that neonatal sevoflurane specifically alters miR-20b and miR-532 profiles in a pattern that differs by brain region and developmental age [29]. Opioids Opioid-based anesthesia is associated with epigenetic changes that may contribute to the development of tolerance, dependence, and postoperative pain sensitization (Table 2). A human clinical study that sampled patients during fentanyl-based general anesthesia for major breast surgery revealed a substantial intraoperative decline in global DNA methylation across the surgical period, highlighting that opioid-containing anesthetic regimens can acutely reshape the blood methylome on a genome-wide scale [36]. In an animal study, repeated morphine dosing within the spinal cord elevated H3K9 acetylation at multiple loci, with the BDNF promoter representing functionally significant target—altered BDNF expression, contributing to synaptic plasticity changes that drive tolerance and hyperalgesia [37]. Preclinical (animal) data from models of chronic cocaine exposure revealed system-wide histone acetylation remodeling that parallels that observed with opioids, supporting the hypothesis that epigenomic reprogramming is a common mechanism through which drugs of dependence reshape the neural circuitry [15]. Consistent with this, pharmacological HDAC blockade attenuates the locomotor sensitization that develops following a single morphine challenge in rodents [16], suggesting that the opioid tolerance phenotype is at least partially epigenomically encoded and therefore potentially reversible. Local anesthetics and regional techniques In addition to their primary sodium channel-blocking mechanisms, local anesthetics have been shown to exert DNA methylation effects (Table 2). In vitro cell-culture experiments established that lidocaine and ropivacaine reduce genomic DNA methylation in breast cancer cell lines in a concentration- and duration-dependent manner, whereas bupivacaine does not share this property [8]. This demethylating activity may influence both nociceptive signaling and tumor biology, and complement the primary pharmacological action of these agents in ways that have not yet been fully characterized clinically. In a human cohort study, epidural analgesia during labor was associated with altered cord-blood DNA methylation patterns at CpG loci linked to offspring asthma susceptibility, with approximately 20 specific sites identified as potential mediators of this association, and roughly half of those sites collectively accounting for more than 50% of the total mediation effect [38]. These findings indicate that regional anesthetic techniques are not epigenomically inert, with implications that may extend to the long-term health of the next generation. Intergenerational considerations Preclinical data have raised a question with profound public health implications: Can anesthetic exposure experienced by a parent alter the epigenome of germ cells that give rise to the next generation? Rodent studies using sevoflurane at various life stages have demonstrated significant epigenomic changes in sperm, including altered transcription factor occupancy [39] and shifts in DNA methylation at stress-axis regulatory loci, including Kcc2, Crhr1, and Nr3c1 [4,40]. Male offspring of exposed fathers exhibit measurably higher anxiety and diminished cognitive performance than controls, and at least some of these heritable phenotypes persist in the F2 generation [39,40]. Whether comparable intergenerational epigenetic effects occur following clinical anesthetic exposure in humans remains unknown. However, preclinical data raise important questions about anesthetic safety in individuals of reproductive age [4,41]. FUTURE DIRECTIONS The interface between epigenetics and anesthesiology can be further shaped by several priority research areas. First, large-scale, well-phenotyped, longitudinal human studies are needed to determine whether the epigenomic changes documented in animal models occur in clinical patients and whether they are of sufficient magnitude and durability to influence patient-centered outcomes [18,19]. Second, the development and validation of epigenetic biomarkers based on cell-free DNA methylation patterns, specific circulating miRNAs, or other accessible epigenomic readouts could transform perioperative risk stratification and postoperative surveillance [42,43]. Third, the pharmacological modulation of anesthesia-induced epigenetic changes through agents such as decitabine (a DNMT inhibitor) or dexmedetomidine (whose neuroprotective properties may, in part, operate through epigenetic mechanisms) represents a potentially important avenue for preventing or reversing adverse perioperative epigenomic outcomes [18,21]. From a research design perspective, the field would benefit from standardized epigenomic measurement protocols across a variety of centers; pre-registration of hypotheses and analysis plans to limit false-positive discovery; and integration of epigenomic data with transcriptomic, proteomic, and clinical outcome data within large cohort repositories. Finally, the intergenerational dimension of anesthetic epigenomics, currently supported only by animal data, warrants dedicated human studies using prospective designs that follow both exposed parents and their subsequently conceived children over meaningful developmental time horizons. CONCLUSION Epigenetics occupies the conceptual space between the fixed genome and the dynamic phenome, providing a mechanistic account of how environmental signals, including pharmacological and physiological perturbations of the perioperative period, are transduced into lasting changes in gene expression. The three principal epigenetic mechanisms (DNA methylation, histone modification, and noncoding RNA regulation) are biochemically distinct but deeply interconnected, forming a unified regulatory network in which any individual anesthetic agent or surgical stressor may simultaneously perturb multiple nodes (Table 1). Practical implications for anesthesiologists are gradually gaining attention. Epigenetic variations partly determine why patients respond differently to the same analgesic regimen, why some individuals are more susceptible to chronic pain or postoperative cognitive dysfunction, and why the immunological consequences of critical illness can outlast acute insults by weeks or months. Incorporating an epigenetic perspective into clinical thinking does not require abandoning established pharmacological principles. Rather, it adds a temporal and cell-biological dimension that helps explain phenomena, such as tolerance, sensitization, and the long-term sequelae of early life exposure, which are otherwise difficult to account for. However, epigenetics is still in its infancy. Many of the most compelling findings were from animal models and require replication in patients with appropriate clinical phenotyping. Nevertheless, the conceptual framework is sufficiently mature to guide both research designs and clinical awareness. Anesthesiologists who understand the fundamental biology of epigenetics are better positioned to ask the relevant clinical questions, interpret the expanding perioperative epigenomics literature, and participate in the development of genuinely mechanism-informed approaches to patient care.